Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, February 16, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Roanna Ruiz Maintained (AVIR) at Hold with Decreased Target to $10 on, Feb 16th, 2022
Roanna Ruiz of SVB Leerink, Maintained "Atea Pharmaceuticals, Inc." (AVIR) at Hold with Decreased Target from $11 to $10 on, Feb 16th, 2022.
Roanna has made no other calls on AVIR in the last 4 months.
There are 2 other peers that have a rating on AVIR. Out of the 2 peers that are also analyzing AVIR, 1 agrees with Roanna's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Eric Joseph of "JP Morgan" Downgraded from Buy to Hold and Decreased Target to $16 on, Wednesday, October 20th, 2021
This is the rating of the analyst that currently disagrees with Roanna
- Matthew Harrison of "Morgan Stanley" Downgraded from Hold to Sell and Decreased Target to $7 on, Thursday, January 6th, 2022
